Published in:
Open Access
01-05-2016
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
Authors:
Richard J. Stopforth, Kirstie L. S. Cleary, Mark S. Cragg
Published in:
Journal of Clinical Immunology
|
Special Issue 1/2016
Login to get access
Abstract
Monoclonal antibodies (mAb) are revolutionising the treatment of many different diseases. Given their differing mode of action compared to most conventional chemotherapeutics and small molecule inhibitors, they possess the potential to be independent of common modes of treatment resistance and can typically be combined readily with existing treatments without dose-limiting toxicity. However, treatments with mAb rarely result in cure and so a full understanding of how these reagents work and can be optimised is key for their subsequent improvement. Here we review how an understanding of the biology of the inhibitory Fc receptor, FcγRIIB (CD32B), is leading to the development of improved mAb treatments.